Microbial biotransformation – an important tool for the study of drug metabolism

Rhys SalterDepartment of Preclinical Development and Safety, Janssen Research and Development LLC, Spring House, PA, USA;

Douglas C. BeshoreDepartment of Global Chemistry, Merck & Co., Inc., West Point, PA, USA;

Steven L. CollettiDepartment of Global Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA;

Liam EvansHypha Discovery Ltd., Berkshire, UK;

Yong GongDepartment of Preclinical Development and Safety, Janssen Research and Development LLC, Spring House, PA, USA;

Roy HelmyDepartment of Pharmacokinetics, Pharmacokinetics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA;

Yong LiuDepartment of Preclinical Development, Merck & Co., Inc., West Point, PA, USA;

Cheri M. MaciolekDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, PA, USA;

Gary MartinDepartment of Global Chemistry, Merck & Co., Inc., Rahway, NJ, USA;

Natasa PajkovicDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, PA, USA;

Richard PhippsHypha Discovery Ltd., Berkshire, UK;

James SmallDepartment of Global Chemistry, Merck & Co., Inc., West Point, PA, USA;

Jonathan SteeleHypha Discovery Ltd., Berkshire, UK;

Ronald de VriesDepartment of Preclinical Development and Safety, Janssen Pharmaceutica, Beerse, Belgium;

Headley WilliamsColwell Canada Corp., Toronto, Canada;

Iain J. MartinDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Boston, MA, USACorrespondence[email protected]

Articles from other publishers (16)